Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia

Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia

Although the treatment of acute myeloid leukemia (AML) has improved significantly, more than half of all patients develop disease that is refractory to intensive chemotherapy1,2. Functional genomics approaches offer a means to discover specific molecules mediating aberrant growth and survival of can...

Full description

Bibliographic Details
Main Authors: Kentsis, Alex, Reed, Casie, Rice, Kim L., Sanda, Takaomi, Rodig, Scott J., Tholouli, Eleni, Christie, Amanda, Valk, Peter J.M., Delwel, Ruud, Ngo, Vu, Kutok, Jeffery L., Dahlberg, Suzanne E., Moreau, Lisa A., Byers, Richard J., Christensen, James G., Woude, George Vande, Licht, Jonathan D., Kung, Andrew L., Staudt, Louis M., Look, A. Thomas
Format: Online
Language:English
Published: 2012
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3438345/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3438345/

Similar Items